Search Results
Your search for AT matches 28914 pages
Showing 5701 - 5750Addition of Vistusertib to Anastrozole for Hormone Receptor–Positive Recurrent or Metastatic Endometrial Cancer
In a French phase I/II trial (VICTORIA) reported in JAMA Oncology, Heudel et al found that the addition of the mTOR inhibitor vistusertib to anastrozole improved outcomes in women with hormone receptor–positive recurrent or metastatic endometrial cancer. As stated by the investigators, “Endometrial ...
Neurologic and Survival Outcomes After Awake Craniotomy for Glioblastoma
In an analysis from the GLIOMAP study reported in The Lancet Oncology, Gerritsen et al found that awake craniotomy for glioblastoma in eloquent brain areas (essential areas for carrying out basic neurological functions) was associated with reduced risk of neurologic deficits and improved survival...
Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors
The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...
Delays in Surgery for Advanced Esophageal Cancer Result in Significantly Worse Survival
Delays in surgery for esophageal cancer did not appear to have much impact on patients’ relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an...
Age at Initiation of Colorectal Cancer Screening and Risk of Colorectal Cancer Among U.S. Women
In a study reported in JAMA Oncology, Ma et al found that the initiation of lower gastrointestinal endoscopy screening in women younger than age 50 was associated with a reduced risk of colorectal cancer vs no screening, and a greater absolute risk reduction compared with screening starting at age...
Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma
A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...
Watch-and-Wait Strategy for Organ Preservation in Patients Receiving Total Neoadjuvant Therapy for Rectal Adenocarcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Garcia-Aguilar et al found that total neoadjuvant therapy followed by a watch-and-wait strategy vs total mesorectal excision based on response allowed for organ preservation in approximately half of patients with rectal...
AYA Leukemia Survivors Have Higher Mortality Rates Than the General Population
Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...
MONALEESA-3: Updated Overall Survival Analysis
On this episode, we’ll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we’ll hear from a researcher about the current state of cancer research and anticipated trends in the field.
Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer
The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...
Prevalence of Plasma Cell and Lymphoproliferative Disorders in Relatives of Probands With Light Chain Amyloidosis
In a study reported in the British Journal of Haematology, Staron et al found that the prevalence of plasma cell and lymphoproliferative disorders among blood relatives of probands with light chain (AL) amyloidosis was low overall and varied according to proband AL amyloidosis subtype. Despite...
3 vs 6 Months of Adjuvant Oxaliplatin- and Fluoropyrimidine-Based Therapy for Stage III Colon Cancer: Final Analysis
As reported in the Journal of Clinical Oncology by Yoshino et al, the final analysis of survival and safety of the Japanese phase III ACHIEVE trial (part of the IDEA Collaboration) has shown no difference in disease-free or overall survival with 3 vs 6 months of adjuvant mFOLFOX6 (fluorouracil,...
Mortality and Perioperative Outcomes With Open vs Robot-Assisted Radical Cystectomy for Bladder Cancer
In a Swedish population-based cohort study reported in JAMA Network Open, Mortezavi et al found that robot-assisted radical cystectomy with intracorporeal urinary diversion was associated with reduced all-cause mortality, reduced high-grade complications, and improved perioperative outcomes vs open ...
Association of Chromosome 3p25.3 Gain With Cisplatin Resistance and Outcomes in Male Malignant Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Timmerman et al found that chromosome 3p25.3 gain was present in all cisplatin-resistant germ cell tumor (GCT) lines in vitro; was more common in patients with relapsed or cisplatin-resistant male type II GCTs; and was associated with poorer...
Patients With NSCLC Brain Metastases Undergoing Neurosurgical Resection: Comparison of Treatment Regimens
In a German single-institution retrospective cohort study reported in JAMA Network Open, Wasilewski et al found that treatment with immune checkpoint inhibition plus radiotherapy was associated with prolonged overall survival vs platinum-based chemotherapy plus radiotherapy in patients with brain...
Sentinel Node May Not Be Informative in Making Treatment Decisions for Some Breast Cancer Subsets
In women aged 70 and older with hormone receptor–positive, HER2-negative, low-risk breast cancers, sentinel lymph node biopsy may not be a reliable indicator of the need for adjuvant chemotherapy, researchers reported at the 2022 American Society of Breast Surgeons Annual Meeting.1 “We found that...
New Research Encourages Harnessing Health Technology to Help Patients With Cancer Quit Smoking
New research published by Ramsey et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that the inclusion of the smoking cessation tool Electronic Health Record–Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) into electronic health records may increase...
Anti–CTLA-4 Antibody–Based Treatment in Patients With Metastatic Melanoma Experiencing Disease Progression on Relatlimab/Nivolumab
In a study reported as a letter to the editor in The New England Journal of Medicine, Alexander M. Menzies, MD, and colleagues found that patients with metastatic melanoma who had progressive disease while receiving relatlimab/nivolumab had poor responses to anti–CTLA-4–based treatment. As noted...
Report Finds Targeting IL-6 May Help to Relieve Immunotherapy Side Effects
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events caused by immunotherapy by targeting the cytokine interleukin-6 (IL-6). The study, published by Hailemichael et al in Cancer Cell, establishes a proof of concept ...
Rehospitalization and Emergency Department Visits After CAR T-Cell Therapy in Commercially Insured Patients With Cancer
In a single-institution study reported in a research letter in JAMA Oncology, Kenzik et al found substantial rates of rehospitalization and emergency department visits after chimeric antigen receptor (CAR) T-cell therapy among commercially insured patients with cancer. Study Details The study...
Ipilimumab/Nivolumab in Patients With Metastatic Pancreatic or Biliary Cancer and HRD Pathogenic Germline Variants
In a single-institution case series reported in a research letter in JAMA Oncology, Terrero et al found that the combination of ipilimumab and nivolumab was active in patients with chemotherapy-refractory metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD)...
Beyond Immunotherapy: New Targeted Agents for Advanced NSCLC
The advent of PD-1 and PD-L1 checkpoint inhibitors has changed the treatment landscape of advanced non–small cell lung cancer (NSCLC), but only approximately 20% of patients treated with immunotherapy will be alive at 5 years. According to Melissa L. Johnson, MD, Director, Lung Cancer Research,...
ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to...
Comparison of 2020 NICE Criteria for Preoperative Radiotherapy in Rectal Cancer Treated by Surgery Alone With Established MRI Prognostic Factors
In a retrospective cohort study reported in The Lancet Oncology, Lord et al found that high-risk patients with rectal cancer treated with surgery alone who were more likely to benefit from preoperative radiotherapy were better selected using proven magnetic resonance imaging (MRI) prognostic...
Trends in Hysterectomy-Corrected Uterine Cancer Mortality and Racial/Ethnic Differences
In a study reported in JAMA Oncology, Clarke et al found that hysterectomy-corrected rates of mortality from uterine corpus cancer overall and from nonendometrioid carcinomas have increased in recent years, with mortality rates being highest in Black women. The study involved data from the U.S....
Addition of Ibandronate to Adjuvant Endocrine Therapy in Postmenopausal Women With ER-Positive Breast Cancer
In the Dutch phase III TEAM-IIB trial reported in the Journal of Clinical Oncology, Sonja B. Vliek, MD, and colleagues found that the addition of oral ibandronate to adjuvant endocrine therapy did not improve disease-free survival in postmenopausal women with estrogen receptor (ER)-positive stage I ...
Second-Line Tislelizumab vs Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti–PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell...
Why Are Black Women Still Dying at Higher Rates Than White Women From Breast Cancer?
What is so dismaying to me is that the statistic on survival for Black women with breast cancer has not changed since I was diagnosed with breast cancer 17 years ago. In 2005, Black women were 41% more likely to die of the disease than White women, even though Black women are less likely to be...
Short and Shorter Screening Tools for Food Insecurity
A survey of oncology registered dietitian nutritionists (RDNs)1 found that most of those surveyed were not using a validated assessment tool to identify food insecurity but expressed interest in obtaining the Six-Item Short Form of the Food Security Survey Module.2 The six-item food insecurity...
Assessing Food Insecurity Among Patients With Cancer
Food insecurity, particularly as it affects cancer survivors, is a serious problem, according to a survey of oncology registered dietitian nutritionists (RDNs) published in the Journal of the Academy of Nutrition and Dietetics.1 “Despite these concerns, most oncology RDNs interviewed are not using...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
From a Small Village in China to Cutting-Edge Clinical Cancer Research for Cynthia X. Ma, MD, PhD
Cynthia X. Ma, MD, PhD, was born in a small village in Hebei, a province in the Central China region. “I grew up in a poor village with less than 1,000 people. We had no medical services in our village, so we had to travel to the city to see a doctor, which was quite some distance away. In the...
DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?
The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...
DESTINY-Lung01: T-DXd Shows Durable Activity in Previously Treated Metastatic HER2-Mutant NSCLC
In a phase II trial (DESTINY-Lung01) reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, of the Thoracic Oncology and Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed...
MSK Introduces The Starr Foundation Program for Discovery Science
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering initiative made possible by a $50 million gift from The Starr Foundation. The program will support the work of scientists at the Sloan Kettering...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. Hear from select award...
Expert Point of View: Barbara S. Norquist, MD
Discussant of the PRIME trial, Barbara S. Norquist, MD, Associate Professor of Obstetrics and Gynecology at the University of Washington, Seattle, noted that although all subgroups in the PRIMA study appeared to derive benefit from niraparib maintenance therapy, patients with homologous...
PRIME Trial: Niraparib Maintenance Therapy Improves Progression-Free Survival in Advanced Ovarian Cancer
A larger population of patients with newly diagnosed advanced ovarian cancer may be able to benefit from niraparib maintenance therapy, with an improved safety profile, according to phase III data presented at the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.1 Results ...
Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treatment with ribociclib plus fulvestrant lengthened overall survival by approximately 16 months vs...
TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
NCCN Announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center Joins Member Institutions
The National Comprehensive Cancer Network® (NCCN®) recently announced that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the not-for-profit alliance of leading cancer centers as the 32nd member institution. NCCN was founded by 13 original Member Institutions in...
Penn Medicine Appoints Robert Vonderheide, MD, DPhil, to Second 5-Year Term as Director of Abramson Cancer Center
Robert H. Vonderheide, MD, DPhil, has been appointed to a second 5-year term as Director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 U.S. Food and Drug Administration approvals in oncology for therapies based on studies...
David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center
Yale Cancer Center and Smilow Cancer Hospital welcome David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology) and a member of the Center for Molecular and Cellular Oncology (CMCO). Dr. Braun cares for patients with kidney cancer. Dr. Braun received his PhD in Computational Biology ...
J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude
J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...
Absence of FAM19A4/miR124-2 DNA Methylation and Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia
In the Dutch CONCERVE study reported in the Journal of Clinical Oncology, Kremer et al found that the absence of FAM19A4/miR124-2 DNA methylation was associated with a high rate of clinical regression of high-grade cervical intraepithelial neoplasia over 24 months among women treated with a...
Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early NSCLC
On March 4, 2022, nivolumab was approved for use with platinum-doublet chemotherapy for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant setting.1 The approval is the first for neoadjuvant therapy for early-stage NSCLC. Supporting Efficacy Data Approval was based on findings from...
AACR Honors Lee Ellis, MD, for Contributions to Education and Training in Cancer Research
The American Association for Cancer Research (AACR) has named Lee Ellis, MD, Professor of Colon and Rectal Surgery at The University of Texas MD Anderson Cancer Center, Houston, as the 2022 recipient of the AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in...
Expert Point of View: Julio Chavez, MD and Hayder Saeed, MD
Julio Chavez, MD, of the Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, was cautiously enthusiastic about these findings in CD30-positive lymphoma. “This clinical trial is novel, as it engages cord blood derived-NK cells to attack CD30-positive tumor cells using a...
Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma
Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...
Treatment De-escalation in HPV-Associated Oropharyngeal Cancer Using Primary Radiotherapy vs Transoral Surgery
As reported in JAMA Oncology by David Palma, MD, PhD, and colleagues, enrollment in the phase II ORATOR2 trial, which was designed to evaluate overall survival after de-escalated treatment with primary radiotherapy vs transoral surgery in human papillomavirus (HPV)-related oropharyngeal squamous...
